Volume Alert - BSX 13.24 Boston Scientific Corp $B
Post# of 122
Posted On: 11/07/2014 11:43:15 PM
Volume Alert - BSX 13.24 Boston Scientific Corp $BSX Hit a high today of 13.36 Closing the day 11/07/14 at 13.24 -0.12 -0.90% With a day low of 13.23 and a total volume of 12,553,243.
BSX Recent Posts: http://investorshangout.com/Boston-Scientific...BSX-50374/
BSX Boston Scientific Corp Recent Headline News
BioScrip (BIOS) Q3 Loss Wider than Expected, Revenues Top - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 2:10PM CST
BioScrip, Inc. (BIOS) recently declared its third-quarter 2014 results.
BSX: 13.24 (-0.12), ICUI: 71.16 (-0.89), ABAX: 51.63 (-2.21), BIOS: 5.69 (+0.17)
Boston Scientific (BSX) Breaks Through Support at $13.31
Comtex SmarTrend(R) - Fri Nov 07, 12:25PM CST
Boston Scientific (NYSE:BSX) has opened bearishly below the pivot of $13.37 today and has reached the first level of support at $13.31. Analysts will be watching for a cross of the next downside pivot targets of $13.27 and $13.17.
BSX: 13.24 (-0.12)
Omnicell Earnings Hit by High Tax, User Addition Aids Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 11:27AM CST
On Nov 7, 2014, we issued an updated research report on Omnicell Inc. (OMCL).
BSX: 13.24 (-0.12), ICUI: 71.16 (-0.89), ABAX: 51.63 (-2.21), OMCL: 31.89 (-0.28)
Wright Medical Posts Wider Q3 Loss; Lowers '14 Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 8:50AM CST
Following the earnings release, shares of Wright Medical Group Inc. (WMGI) dropped nearly 5.7% to close at $28.44 yesterday.
BSX: 13.24 (-0.12), WMGI: 27.95 (-0.49), GWPH: 73.97 (-0.41), ABAX: 51.63 (-2.21)
2 Health Care Stocks to Watch on GOP Congressional Takeover - Stocks in the News
Zacks Research Staff - Zacks Investment Research - Thu Nov 06, 4:02PM CST
These health care stocks could benefit if Republicans push for changes in the medical sector.
BSX: 13.24 (-0.12), SYK: 87.47 (-1.08), HUM: 130.58 (-9.29)
Technical Coverage on Health Care Equipment Stocks - Boston Scientific, Zeltiq Aesthetics, Globus Medical, Volcano, and Stryker
PR Newswire - Thu Nov 06, 7:45AM CST
Investor-Edge has initiated coverage on the following equities: Boston Scientific Corporation (NYSE: BSX), Zeltiq Aesthetics Inc. (NASDAQ: ZLTQ), Globus Medical Inc. (NYSE: GMED), Volcano Corporation (NASDAQ: VOLC), and Stryker Corporation (NYSE: SYK). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Wednesday, November 5, 2014, the NASDAQ Composite ended at 4,620.72, down 0.06%, the Dow Jones Industrial Average advanced 0.58%, to finish the day at 17,484.53, and the S&P 500 closed at 2,023.57, up 0.57%. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 778.22, down 0.19%, while the index has advanced 10.98% in the previous three months. Register for your complimentary reports on these five stocks at:
BSX: 13.24 (-0.12), ZLTQ: 27.49 (-0.25), GMED: 21.48 (-0.58), VOLC: 9.99 (+0.07), SYK: 87.47 (-1.08)
GOP Win Lifts TransCanada, Medical Device, Coal Stocks
at Investor's Business Daily - Wed Nov 05, 1:35PM CST
Prospects for approval of the Keystone XL pipeline, and for Calgary-based pipeline operator TransCanada (TRP), brightened after the GOP gained control of the Senate Tuesday. The power shift in Washington is also expected to benefit medical device...
BSX: 13.24 (-0.12), BTU: 11.64 (+0.80), MDT: 68.10 (-0.64), TRP: 49.40 (+0.18), STJ: 64.76 (-1.28), ANR: 2.91 (+0.39)
Insider Trading Alert - LLY, CRUS And BSX Traded By Insiders
at The Street - Wed Nov 05, 10:24AM CST
Stocks with insider trader activity include LLY, CRUS and BSX
BSX: 13.24 (-0.12), CRUS: 19.55 (-0.26), LLY: 66.60 (-0.36)
Republicans Grab Senate: Which Stocks Will Fare Well? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 8:19AM CST
The Republican win will certainly bolster stocks and give investors more chances to earn.
GD: 140.14 (-1.42), LMT: 186.15 (-3.73), MDT: 68.10 (-0.64), QDEL: 27.87 (-0.80), XOM: 96.59 (+0.33), CLF: 11.17 (+0.63), BA: 124.45 (-0.13), NUVA: 41.75 (-0.18), ANR: 2.91 (+0.39), BSX: 13.24 (-0.12), VLO: 50.72 (+0.48), BTU: 11.64 (+0.80), ABAX: 51.63 (-2.21), IMO: 47.63 (+0.74), ACI: 2.86 (+0.44)
Quarterly Financial Results and Upcoming Conference - Research Reports on Mylan, Aegerion, Bard, Incyte and Boston Scientific
PR Newswire - Wed Nov 05, 7:50AM CST
Today, Analysts Review released its research reports regarding Mylan Inc. (NASDAQ: MYL), Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), C.R. Bard, Inc. (NYSE: BCR), Incyte Corporation (NASDAQ: INCY) and Boston Scientific Corporation (NYSE: BSX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7704-100free.
BSX: 13.24 (-0.12), BCR: 162.38 (-2.59), INCY: 69.32 (+0.92), MYL: 53.11 (-0.39), AEGR: 21.58 (-0.40)
Boston Scientific To Participate In 2014 Stifel Healthcare Conference
PR Newswire - Wed Nov 05, 7:30AM CST
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2014 Stifel Healthcare Conference on Tuesday, November 18, 2014 in New York City. Dan Brennan, executive vice president and chief financial officer, will participate in a 30-minute question and answer session regarding the company beginning at approximately 9:10 a.m. ET.
BSX: 13.24 (-0.12)
CVS Health Beats Q3 Earnings, Revenues; Narrows Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 1:00PM CST
CVS Health Corporation (CVS) ??? formerly known as CVS Caremark ??? reported third-quarter 2014 adjusted earnings per share (EPS) of $1.15.
BSX: 13.24 (-0.12), ICUI: 71.16 (-0.89), ABAX: 51.63 (-2.21), CVS: 88.38 (-0.05)
Haemonetics Q2 Earnings Beat Estimates but Decline Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 12:20PM CST
Haemonetics Corporation (HAE) reported adjusted earnings of 47 cents per share in the second quarter of fiscal 2015.
BSX: 13.24 (-0.12), ICUI: 71.16 (-0.89), ABAX: 51.63 (-2.21), HAE: 36.82 (-0.27)
Boston Scientific (BSX) Approaches New Downside Target of $13.17
Comtex SmarTrend(R) - Tue Nov 04, 10:15AM CST
Shares of Boston Scientific (NYSE:BSX) opened today below their pivot of $13.29 and have already reached the first level of support at $13.24. Should the shares continue to fall, the support pivots of $13.17 and $13.05 will be of interest.
BSX: 13.24 (-0.12)
Boston Scientific To Host And Webcast Investor Event
PR Newswire - Tue Nov 04, 7:30AM CST
Boston Scientific Corporation (NYSE: BSX) today announced that it will be holding an analyst event on November 19, 2014 to provide an update on company interventional cardiology initiatives and discuss data from the EVOLVE II study, the pivotal trial designed to support SYNERGY(TM) Stent System approval by the FDA. EVOLVE II data will be presented in a Late-Breaking Clinical Trial presentation on November 19 at 10:55am CT at the 2014 American Heart Association Scientific Sessions. The Boston Scientific investor event and webcast, which will include a question and answer session, is scheduled to begin at 1:00 p.m. CT and adjourn at approximately 2:00 p.m. CT.
BSX: 13.24 (-0.12)
Mead Johnson Tumbles as Danone Goes for Yashili in China - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 10:20AM CST
Pediatric nutrition products provider Mead Johnson Nutrition Company's (MJN) shares dropped 4.1% to close at $99.31 on Friday.
BSX: 13.24 (-0.12), MJN: 98.39 (-0.45), GWPH: 73.97 (-0.41), ABAX: 51.63 (-2.21)
Boston Scientific (BSX) Stock Dips In Pre-Market Trading on First Day of Medical DeviceTrial
at The Street - Mon Nov 03, 8:27AM CST
Boston Scientific (BSX) shares are down on the first day of civil trials brought against the company over alleged defects of its transvaginal mesh device.
BSX: 13.24 (-0.12)
Boston Scientific Announces Schedule For Presentations At The Upcoming North American Neuromodulation Society (NANS) Meeting
PR Newswire - Mon Nov 03, 8:00AM CST
Boston Scientific Corporation (NYSE: BSX) is reinforcing the company's commitment to developing innovative and effective therapies in neuromodulation. The company will present data on key clinical programs at the 18th North American Neuromodulation Society (NANS) Meeting, being held this year in Las Vegas, December 11-14.
BSX: 13.24 (-0.12)
Merge Healthcare Q3 Revenues Top Estimates, Earnings Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 2:10PM CDT
Merge Healthcare Incorporated (MRGE) reported third-quarter 2014 adjusted net income per share of 4 cents.
BSX: 13.24 (-0.12), ICUI: 71.16 (-0.89), ABAX: 51.63 (-2.21), MRGE: 3.06 (+0.03)
Boston Scientific (BSX) Breaks Through Resistance at $13.24
Comtex SmarTrend(R) - Fri Oct 31, 9:32AM CDT
Shares of Boston Scientific (NYSE:BSX) have bullishly opened above the pivot of $13.15 today and have reached the first resistance level of $13.24. Should the shares continue to rise, the resistance pivots of $13.30 and $13.45 will be of interest.
BSX: 13.24 (-0.12)
BSX Recent Posts: http://investorshangout.com/Boston-Scientific...BSX-50374/
BSX Boston Scientific Corp Recent Headline News
BioScrip (BIOS) Q3 Loss Wider than Expected, Revenues Top - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 2:10PM CST
BioScrip, Inc. (BIOS) recently declared its third-quarter 2014 results.
BSX: 13.24 (-0.12), ICUI: 71.16 (-0.89), ABAX: 51.63 (-2.21), BIOS: 5.69 (+0.17)
Boston Scientific (BSX) Breaks Through Support at $13.31
Comtex SmarTrend(R) - Fri Nov 07, 12:25PM CST
Boston Scientific (NYSE:BSX) has opened bearishly below the pivot of $13.37 today and has reached the first level of support at $13.31. Analysts will be watching for a cross of the next downside pivot targets of $13.27 and $13.17.
BSX: 13.24 (-0.12)
Omnicell Earnings Hit by High Tax, User Addition Aids Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 11:27AM CST
On Nov 7, 2014, we issued an updated research report on Omnicell Inc. (OMCL).
BSX: 13.24 (-0.12), ICUI: 71.16 (-0.89), ABAX: 51.63 (-2.21), OMCL: 31.89 (-0.28)
Wright Medical Posts Wider Q3 Loss; Lowers '14 Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 8:50AM CST
Following the earnings release, shares of Wright Medical Group Inc. (WMGI) dropped nearly 5.7% to close at $28.44 yesterday.
BSX: 13.24 (-0.12), WMGI: 27.95 (-0.49), GWPH: 73.97 (-0.41), ABAX: 51.63 (-2.21)
2 Health Care Stocks to Watch on GOP Congressional Takeover - Stocks in the News
Zacks Research Staff - Zacks Investment Research - Thu Nov 06, 4:02PM CST
These health care stocks could benefit if Republicans push for changes in the medical sector.
BSX: 13.24 (-0.12), SYK: 87.47 (-1.08), HUM: 130.58 (-9.29)
Technical Coverage on Health Care Equipment Stocks - Boston Scientific, Zeltiq Aesthetics, Globus Medical, Volcano, and Stryker
PR Newswire - Thu Nov 06, 7:45AM CST
Investor-Edge has initiated coverage on the following equities: Boston Scientific Corporation (NYSE: BSX), Zeltiq Aesthetics Inc. (NASDAQ: ZLTQ), Globus Medical Inc. (NYSE: GMED), Volcano Corporation (NASDAQ: VOLC), and Stryker Corporation (NYSE: SYK). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Wednesday, November 5, 2014, the NASDAQ Composite ended at 4,620.72, down 0.06%, the Dow Jones Industrial Average advanced 0.58%, to finish the day at 17,484.53, and the S&P 500 closed at 2,023.57, up 0.57%. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 778.22, down 0.19%, while the index has advanced 10.98% in the previous three months. Register for your complimentary reports on these five stocks at:
BSX: 13.24 (-0.12), ZLTQ: 27.49 (-0.25), GMED: 21.48 (-0.58), VOLC: 9.99 (+0.07), SYK: 87.47 (-1.08)
GOP Win Lifts TransCanada, Medical Device, Coal Stocks
at Investor's Business Daily - Wed Nov 05, 1:35PM CST
Prospects for approval of the Keystone XL pipeline, and for Calgary-based pipeline operator TransCanada (TRP), brightened after the GOP gained control of the Senate Tuesday. The power shift in Washington is also expected to benefit medical device...
BSX: 13.24 (-0.12), BTU: 11.64 (+0.80), MDT: 68.10 (-0.64), TRP: 49.40 (+0.18), STJ: 64.76 (-1.28), ANR: 2.91 (+0.39)
Insider Trading Alert - LLY, CRUS And BSX Traded By Insiders
at The Street - Wed Nov 05, 10:24AM CST
Stocks with insider trader activity include LLY, CRUS and BSX
BSX: 13.24 (-0.12), CRUS: 19.55 (-0.26), LLY: 66.60 (-0.36)
Republicans Grab Senate: Which Stocks Will Fare Well? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 8:19AM CST
The Republican win will certainly bolster stocks and give investors more chances to earn.
GD: 140.14 (-1.42), LMT: 186.15 (-3.73), MDT: 68.10 (-0.64), QDEL: 27.87 (-0.80), XOM: 96.59 (+0.33), CLF: 11.17 (+0.63), BA: 124.45 (-0.13), NUVA: 41.75 (-0.18), ANR: 2.91 (+0.39), BSX: 13.24 (-0.12), VLO: 50.72 (+0.48), BTU: 11.64 (+0.80), ABAX: 51.63 (-2.21), IMO: 47.63 (+0.74), ACI: 2.86 (+0.44)
Quarterly Financial Results and Upcoming Conference - Research Reports on Mylan, Aegerion, Bard, Incyte and Boston Scientific
PR Newswire - Wed Nov 05, 7:50AM CST
Today, Analysts Review released its research reports regarding Mylan Inc. (NASDAQ: MYL), Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), C.R. Bard, Inc. (NYSE: BCR), Incyte Corporation (NASDAQ: INCY) and Boston Scientific Corporation (NYSE: BSX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7704-100free.
BSX: 13.24 (-0.12), BCR: 162.38 (-2.59), INCY: 69.32 (+0.92), MYL: 53.11 (-0.39), AEGR: 21.58 (-0.40)
Boston Scientific To Participate In 2014 Stifel Healthcare Conference
PR Newswire - Wed Nov 05, 7:30AM CST
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2014 Stifel Healthcare Conference on Tuesday, November 18, 2014 in New York City. Dan Brennan, executive vice president and chief financial officer, will participate in a 30-minute question and answer session regarding the company beginning at approximately 9:10 a.m. ET.
BSX: 13.24 (-0.12)
CVS Health Beats Q3 Earnings, Revenues; Narrows Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 1:00PM CST
CVS Health Corporation (CVS) ??? formerly known as CVS Caremark ??? reported third-quarter 2014 adjusted earnings per share (EPS) of $1.15.
BSX: 13.24 (-0.12), ICUI: 71.16 (-0.89), ABAX: 51.63 (-2.21), CVS: 88.38 (-0.05)
Haemonetics Q2 Earnings Beat Estimates but Decline Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 12:20PM CST
Haemonetics Corporation (HAE) reported adjusted earnings of 47 cents per share in the second quarter of fiscal 2015.
BSX: 13.24 (-0.12), ICUI: 71.16 (-0.89), ABAX: 51.63 (-2.21), HAE: 36.82 (-0.27)
Boston Scientific (BSX) Approaches New Downside Target of $13.17
Comtex SmarTrend(R) - Tue Nov 04, 10:15AM CST
Shares of Boston Scientific (NYSE:BSX) opened today below their pivot of $13.29 and have already reached the first level of support at $13.24. Should the shares continue to fall, the support pivots of $13.17 and $13.05 will be of interest.
BSX: 13.24 (-0.12)
Boston Scientific To Host And Webcast Investor Event
PR Newswire - Tue Nov 04, 7:30AM CST
Boston Scientific Corporation (NYSE: BSX) today announced that it will be holding an analyst event on November 19, 2014 to provide an update on company interventional cardiology initiatives and discuss data from the EVOLVE II study, the pivotal trial designed to support SYNERGY(TM) Stent System approval by the FDA. EVOLVE II data will be presented in a Late-Breaking Clinical Trial presentation on November 19 at 10:55am CT at the 2014 American Heart Association Scientific Sessions. The Boston Scientific investor event and webcast, which will include a question and answer session, is scheduled to begin at 1:00 p.m. CT and adjourn at approximately 2:00 p.m. CT.
BSX: 13.24 (-0.12)
Mead Johnson Tumbles as Danone Goes for Yashili in China - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 10:20AM CST
Pediatric nutrition products provider Mead Johnson Nutrition Company's (MJN) shares dropped 4.1% to close at $99.31 on Friday.
BSX: 13.24 (-0.12), MJN: 98.39 (-0.45), GWPH: 73.97 (-0.41), ABAX: 51.63 (-2.21)
Boston Scientific (BSX) Stock Dips In Pre-Market Trading on First Day of Medical DeviceTrial
at The Street - Mon Nov 03, 8:27AM CST
Boston Scientific (BSX) shares are down on the first day of civil trials brought against the company over alleged defects of its transvaginal mesh device.
BSX: 13.24 (-0.12)
Boston Scientific Announces Schedule For Presentations At The Upcoming North American Neuromodulation Society (NANS) Meeting
PR Newswire - Mon Nov 03, 8:00AM CST
Boston Scientific Corporation (NYSE: BSX) is reinforcing the company's commitment to developing innovative and effective therapies in neuromodulation. The company will present data on key clinical programs at the 18th North American Neuromodulation Society (NANS) Meeting, being held this year in Las Vegas, December 11-14.
BSX: 13.24 (-0.12)
Merge Healthcare Q3 Revenues Top Estimates, Earnings Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 2:10PM CDT
Merge Healthcare Incorporated (MRGE) reported third-quarter 2014 adjusted net income per share of 4 cents.
BSX: 13.24 (-0.12), ICUI: 71.16 (-0.89), ABAX: 51.63 (-2.21), MRGE: 3.06 (+0.03)
Boston Scientific (BSX) Breaks Through Resistance at $13.24
Comtex SmarTrend(R) - Fri Oct 31, 9:32AM CDT
Shares of Boston Scientific (NYSE:BSX) have bullishly opened above the pivot of $13.15 today and have reached the first resistance level of $13.24. Should the shares continue to rise, the resistance pivots of $13.30 and $13.45 will be of interest.
BSX: 13.24 (-0.12)
(0)
(0)Boston Scientific Corporation (BSX) Stock Research Links
Scroll down for more posts ▼